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ABSTRACT  
The protease ADAMTS7 functions in the 
extracellular matrix (ECM) of the cardiovascular 
system. However, its physiological substrate 
specificity and mechanism of regulation remain to 
be explored. To address this, we conducted an 
unbiased substrate analysis using terminal amine 
isotopic labeling of substrates (TAILS). The 
analysis identified candidate substrates of 
ADAMTS7 in the human fibroblast secretome, 
including proteins with a wide range of functions, 
such as collagenous and non-collagenous ECM 
proteins, growth factors, proteases, and cell-surface 
receptors. It also suggested that autolysis occurs at 
Glu729–Val730 and Glu732-Ala733 in the 
ADAMTS7 spacer domain, which was 
corroborated by N-terminal sequencing and 
western blotting. Importantly, TAILS also 
identified proteolysis of the latent TGF-β–binding 
proteins 3 and 4 (LTBP3/4) at a Glu–Val and Glu–
Ala site, respectively. Using purified enzyme and 
substrate, we confirmed ADAMTS7-catalyzed 
proteolysis of recombinant LTBP4. Moreover, we 
identified multiple additional scissile bonds in an 
N-terminal linker region of LTBP4 that connects 
fibulin-5/tropoelastin and fibrillin-1–binding 
regions, which have an important role in 
elastogenesis. ADAMTS7-mediated cleavage of 
LTBP4 was efficiently inhibited by the 
metalloprotease inhibitor TIMP-4, but not by 
TIMP-1 and less efficiently by TIMP-2 and TIMP-
3. As TIMP-4 expression is prevalent in 
cardiovascular tissues, we propose that TIMP-4 
represents the primary endogenous ADAMTS7 
inhibitor. In summary, our findings reveal LTBP4 
as an ADAMTS7 substrate, whose cleavage may 
potentially impact elastogenesis in the 
cardiovascular system. We also identify TIMP-4 as 
a likely physiological ADAMTS7 inhibitor. 
 
ADAMTS7 is an extracellular 
metalloprotease and one of 19 human ADAMTS 
family members (1). It is a large protein (>250 
kDa), consisting of 15 domains (Fig 1A). A 
Prodomain, located N-terminal to the 
metalloprotease (MP) domain, is predicted to 
maintain latency until it is removed by proprotein 
convertases. The MP domain is typical for that of 
metzincin metalloproteases, which contain an 
active site of three histidines and a catalytic 
glutamic acid (2). The domains C-terminal of the 
MP domain most likely provide exosites that 
enhance substrate binding and specificity, based on 
studies of other ADAMTS family members (3-5). 
The physiological function of ADAMTS7 is 
not known, but recent evidence shows that it 
functions in the extracellular matrix (ECM) of 
cardiovascular tissues (6-10). Analysis of normal 
expression of ADAMTS7 in healthy adult tissues 
shows it is predominantly expressed in the heart 
and in the tunica media of the lung vasculature, but 
also at lower levels in other tissues, including 
tendon (1,7,11). In the arterial wall, ADAMTS7 is 
upregulated in response to injury/inflammation 
(7,8). In this setting, it influences vascular smooth 
muscle cell (VSMC) migration, possibly by 
affecting the composition/integrity of the 
extracellular matrix (ECM) and/or by influencing 
the availability of growth factors. Genome Wide 
Association Studies (GWAS) have established 
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ADAMTS7 as a susceptibility locus for coronary 
artery disease (CAD)(6,12) and atherosclerosis is 
reduced in Adamts7-/- mice (7). ADAMTS7 has 
been detected around VSMCs (and macrophages) 
in human atherosclerotic plaques and elevated 
ADAMTS7 staining in the vessel wall has been 
associated with a high-risk plaque phenotype 
(7,9,13).  
Physiologically, protease activity is often 
regulated by endogenous inhibitors. Several 
metalloprotease families are regulated by the 
Tissue Inhibitor of Metalloprotease (TIMP) family 
of inhibitors, which in humans consist of four 
members (TIMP1-4)(14). Whereas all four TIMPs 
inhibit many members of the Matrix 
Metalloprotease (MMP) family, ADAMTS1,2,4 
and 5 are only inhibited by TIMP-3 (14). For 
ADAMTS7, like most other ADAMTS family 
members, inhibition by TIMPs has not been 
investigated.   
The substrate specificity of ADAMTS7 is 
poorly characterised. Only two proteins, cartilage 
oligomeric matrix protein (COMP) and 
thrombospondin 1 (TSP1) have previously been 
reported as substrates, without identification of 
cleavage sites (10,15). Moreover, a comprehensive 
analysis of the substrate repertoire and cleavage 
sites of ADAMTS7 has not been conducted. 
Knowledge of the cleavage sites is important for 
the understanding of the functional consequences 
of proteolysis. It can also guide the design of 
(therapeutic) inhibitors that derive selectivity and 
potency from mimicking substrate residues 
flanking the cleavage site. It is essential to identify 
the physiological targets of ADAMTS7 to enable a 
causal link to be established between ADAMTS7 
function and CAD/atherosclerosis. To this end, we 
used Terminal Amine Isotopic Labelling of 
Substrates (TAILS), which is a method that 
employs the labelling of neo-N termini generated 
by proteolysis to identify and quantify cleavage 




TAILS analysis  
To study the substrate specificity of 
ADAMTS7, we employed TAILS. For this, 
recombinant ADAMTS7 and truncated variants 
thereof were generated and expressed (Fig 1). The 
truncated variant ADAMTS7-Mu, which consists 
of the first ten N-terminal domains, was expressed 
at the highest levels and was therefore used in this 
study. As a control for proteolysis, we generated an 
inactive variant, ADAMTS7-Mu(E389Q) in which 
the glutamic acid in the active site of the MP 
domain (Glu389) is mutated to glutamine, a 
mutation commonly made to render metzincin 
proteases inactive (2). As a source of endogenously 
expressed extracellular matrix substrates we used 
human fibroblasts. These were co-cultured with 
HEK cells stably transfected with either 
ADAMTS7-Mu or the inactive ADAMTS7-
Mu(E389Q) for 48 hours and the conditioned 
medium was used for iTRAQ labelling of new N-
termini that are generated by proteolysis. Analysis 
of the LC-MS/MS results identified forty-five 
extracellular and transmembrane proteins that 
exhibited evidence of increased proteolysis in the 
presence of ADAMTS7-Mu versus ADAMTS7-
Mu(E389Q) (Table S1). This list of candidate 
substrates includes proteins with a wide range of 
functions, such as collagenous and non-
collagenous ECM proteins, growth factors, 
proteases and cell surface receptors. Interestingly, 
ADAMTS7 itself was among the candidate 
substrates (Table S2), suggesting autolytic 
reactions. Although enrichment of neo-N termini in 
the presence of active ADAMTS7 suggests that the 
new N-terminus results from proteolysis by 
ADAMTS7, targets require verification, as indirect 
effects such as the upregulation or activation of 
other proteases provide alternative explanations.  
Autolysis at Glu-Ala/Val bonds 
To verify that ADAMTS7 cleaves itself, as 
suggested by TAILS, we reassessed the Western 
blot of one of the truncated ADAMTS7 variants, 
ADAMTS7-T4, which also showed potential 
evidence of autolysis (Fig 1C). This variant lacks 
the highly glycosylated mucin-like domain, which 
greatly reduces the molecular weight (MW) of any 
C-terminal fragment arising from autolysis that can 
be detected with an anti-myc tag antibody (Ab). On 
Western blot of ADAMTS7-T4, detecting with an 
anti-myc Ab, a band corresponding to the zymogen 
(>110 kDa), which has the Prodomain still 
attached, was resolved from the mature, active 
form (<110 kDa), which has the Prodomain 
removed (Fig 2A). An unexpected, low MW band 
of 45 kDa, we hypothesised, could be a product of 
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autolysis. This band would correspond to a C-
terminal cleavage product generated by autolysis in 
the Spacer domain. To confirm the identity of these 
bands, ADAMTS7-T4 was incubated with furin, a 
subtilisin-like proprotein convertase which is 
responsible for Prodomain removal in the 
ADAMTS family (1,17). The >110 kDa band, 
corresponding to the ADAMTS7 zymogen, 
disappeared after incubation with furin (Fig 2A). In 
addition, the mature form (<110 kDa) and the 
suspected autolytic cleavage product (45 kDa), 
were both absent when the furin inhibitor 
Decanoyl-RVKR-CMK was added during 
expression. Moreover, a mutant in which the furin 
cleavage sites were mutated, FCSM 
(R68A/R70A/R232A/R236A), also showed the 
>110 kDa band (zymogen) only, which confirms 
that the Prodomain maintains latency and thus 
prevents generation of the 45 kDa autolytic 
cleavage product. The inactive ADAMTS7-
T4(E389Q) variant also lacked the 45 kDa band, 
further confirming its generation is dependent on 
ADAMTS7 activity.  
To identify the scissile bond that is targeted 
in this autolytic reaction, we isolated the 45 kDa 
cleavage product for N-terminal sequencing. The 
N-terminal sequence was identified as “AANFL”, 
which matches an abundant autolytic product 
identified by TAILS (AANFLALR) (Table S2). 
This new N-terminus is generated by autolysis at 
the Glu732-Ala733 bond in the Spacer domain. 
Interestingly, the adjacent and similar Glu729-
Val730 bond is also a major target, as demonstrated 
by abundant VAEAANFLALR peptide identified 
by TAILS.  
As both the Glu729-Val730 and the Glu732-
Ala733 bond contain a glutamic acid residue in the 
P1 position, we mutated these to alanine to 
investigate the preference of ADAMTS7 for a 
glutamic acid residue in P1. The mutant 
ADAMTS7-T4 (E729A/E732A) showed markedly 
reduced autolysis (Fig. 2B), showing that glutamic 
acid residues are better accommodated in the S1 
pocket of ADAMTS7, compared to alanine. 
However, a faint 45 kDa band was still visible, 
showing that Ala in P1 permits proteolysis, but at a 
reduced rate.  
To visualise the location of these autolytic 
cleavage sites in the structure of ADAMTS7, we 
modelled the structure of the N-terminal domains 
of ADAMTS7 (MP-Spacer) using the structure of 
ADAMTS13 as a template. This revealed that the 
Glu729-Val730 and Glu732-Ala733 bonds are both 
present in what is predicted to be the surface 
exposed β3-β4 loop of the Spacer domain, which is 
in line with their susceptibility to proteolysis (Fig 
3). This also suggests that the autolytic reaction 
may have functional consequences as this Spacer 
region contains a substrate binding exosite in 
ADAMTS13 (18-20).  
 
ADAMTS7 cleaves LTBP4 
In addition to the autolytic cleavage 
fragments, TAILS identified forty-five other 
extracellular matrix proteins that exhibited 
evidence of increased proteolysis in the presence of 
active ADAMTS7 (Table S1). To confirm that 
these findings were a direct consequence of 
proteolysis by ADAMTS7, we selected candidate 
substrates for further study. Selection was based on 
the nature of the scissile bonds, the location of the 
cleavage within the protein, potential functional 
consequences of proteolysis and tissue distribution.   
Two related proteins, the latent TGF-β 
binding proteins (LTBP) 3 and 4 were cleaved at 
Glu-Val and Glu-Ala respectively, matching the 
most prominent and confirmed autolytic cleavage 
sites in ADAMTS7 (Glu729-Val730 and Glu732-
Ala733). A sequence alignment of the two proteins 
showed LTBP3 and LTBP4 were both cleaved in 
the same linker region, between the first EGF-like 
domain and the hybrid domain (Fig 4A). That the 
cleavage appeared to occur in a linker region 
between domains suggested that proteolysis is 
expected to separate the two cleavage fragments. 
For LTBP4, this could potentially affect the 
function of LTBP4 in elastic fibre 
formation/organisation. Physiologically, LTBP4 
contributes to the deposition of tropoelastin on 
fibrillin-1 microfibrils (21). This occurs by binding 
of the N-terminal domains of LTBP4 to the fibulin-
5/tropoelastin complex and binding of the C-
terminal domains of LTBP4 to fibrillin-1 (22). 
Cleavages by ADAMTS7, therefore, have the 
potential to separate the fibulin-5/elastin binding 
region from its fibrillin-1 binding region, thereby 
disrupting its essential bridging function. 
Importantly, LTBP4 is also co-expressed with 
ADAMTS7 in the adult heart and lung (23).  
For these reasons, we decided to further 
investigate the apparent proteolysis of LTBP4 by 
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ADAMTS7. An N-terminal fragment of LTBP4 
(LTBP4S-A) that lacks domains C-terminal of the 
hybrid domain was expressed in HEK293T cells 
and the conditioned medium incubated with 
ADAMTS7-T8, ADAMTS7-Mu or the inactive 
variant ADAMTS7-Mu (E389Q). Analysis by non-
reducing Western blot showed LTBP4S-A 
cleavage when incubated with ADAMTS7-Mu or 
ADAMTS7-T8 but not with the inactive control 
ADAMTS7-Mu (E389Q) (Fig 4B). Coomassie- 
stained SDS-PAGE analysis of purified LTBP4S-
A cleaved by 10 nM purified ADAMTS7-T8 
showed multiple cleavage fragments after 8-hour 
incubation (Fig 4C). These results show that 
LTBP4 is cleaved by low nM concentrations of 
ADAMTS7 and is therefore a potential 
physiological substrate.  
The presence of multiple bands following 
digestion of LTBP4 by ADAMTS7 suggests the 
presence of additional cleavage sites. Therefore, 
cleaved and uncleaved LTBP4S-A were labelled 
with Tandem Mass Tags (TMT) at the N-termini 
and analysed by LC-MS/MS. TMT labelled 
peptides (Table S3) revealed a total of twelve 
scissile bonds, predominantly containing 
hydrophobic residues Ala, Val and Leu in P1’ (Fig 
4D), strongly suggesting these are the preferred 
residues in P1’ for ADAMTS7. P1 residues 
included Glu, but also Arg, Ala, Pro and Gly.  
 
TIMP-4 is an efficient inhibitor of ADAMTS7 
Inhibition of ADAMTS7 by endogenous 
metalloprotease inhibitors (TIMPs) has not been 
investigated. We therefore investigated if LTPB4S-
A cleavage by ADAMTS7 can be specifically 
inhibited by TIMP members. This revealed that of 
the four TIMPs, TIMP-4 is the most potent 
inhibitor of ADAMTS7 (Fig 5A). TIMP-3 showed 
moderate inhibition and TIMP-1 and TIMP-2 little 
to no inhibition.  To quantify these differences, 
proteolysis was monitored by densitometry of 
LTBP4S-A on SDS-PAGE/Coomassie. This 
showed that in this assay the apparent inhibition 
constant Ki(app) for TIMP-4 was 13 nM, compared 
to 49 nM for TIMP-3 and >100 nM for TIMP-2 
(Fig 5B). These findings confirm that for 
ADAMTS7, contrary to other ADAMTS family 
members, TIMP-4 is the most potent inhibitor.  
 
Discussion 
Recently, ADAMTS7 has emerged as a 
modifier of CAD (7,24). However, its substrate 
specificity is poorly defined and knowledge of 
cleavage sites is required to understand its 
physiological role. Here, for the first time, we 
report scissile bonds targeted by ADAMTS7. 
These include the autolytic cleavage sites Glu732-
Ala733 and Glu729-Val730. We also identified 
LTBP4 as a novel substrate for ADAMTS7. In 
LTBP4, the P1’ residues were also predominantly 
Ala and Val, suggesting they are favoured in P1’. 
Several different LTBP4 residues were found in P1, 
including Glu, Ala, Arg and Pro. However, 
mutagenesis of the ADAMTS7 residues Glu729 
and Glu730 to Ala reduced autolysis, which shows 
that ADAMTS7 prefers Glu over Ala at the P1 
position. Together, these results shed light on the 
previously unknown cleavage site specificity of 
ADAMTS7. This may also benefit the 
development of small molecule inhibitors, which 
generally target the so-called specificity pocket 
(S1’) in metalloproteases (25). It has been 
suggested that small molecule inhibitors of 
ADAMTS7 could have therapeutic potential in 
CAD (24,26) given that Adamts7-/- mice have 
reduced atherosclerosis in hyperlipidemic mouse 
models (7). Importantly, the identified cleavage 
sites in LTBP4 allow the development of neo-
epitope antibodies to study whether proteolysis 
occurs at these sites in vivo. Evidence that this may 
be the case comes from a proteomic analysis of 
human aorta which identified LTBP4 peptides 
derived from cleavage events at the sites we 
identified (E195↓Ala196 and Ala196↓Ala197) 
(27,28).  
We showed that ADAMTS7 cleaves LTBP4 
in a way that separates the fibulin-5/elastin binding 
region from its fibrillin-1 binding region and could, 
therefore, affect the deposition of Tropoelastin on 
fibrillin-1 microfibrils (21,29). Whether this occurs 
in physiological and/or pathological situations 
needs further investigation. However, ADAMTS7 
and LTBP4 have overlapping tissue expression 
patterns, most notably in cardiac and lung tissue 
(7,23), suggesting this could be the case. The 
enzyme concentration at which we detect 
proteolysis (low nM) also suggests that this could 
be physiologically relevant. Interestingly, several 
other ADAMTS and ADAMTS-like proteins have 
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been implicated in fibrillin-1 microfibril biology, 
including ADAMTS10, ADAMTS17 and 
ADAMTS6  (30-33). Phylogenetic analysis of 
ADAMTS genes shows that ADAMTS7 and 12 are 
more closely related to ADAMTS17/19/6 and 10 
than to the other thirteen ADAMTS family 
members (34), which may indicate a functional 
relationship, like that between ADAMTS1, 4 and 5 
which are all are all involved in versican and 
aggrecan turnover.  
Autolysis has been reported for several 
ADAMTS family members (3,35-37). For 
ADAMTS4 and ADAMTS5, this also involved 
cleavages in the Spacer domain (35,36). Here, we 
show that cleavage of the Glu732-Ala733 and 
Glu729-Val730 in the ADAMTS7 Spacer domain 
is dependent on ADAMTS7 activity. Our LTBP4 
cleavage data further confirmed that ADAMTS7 is 
capable of cleaving Glu-Ala bonds. These findings 
strongly suggest that ADAMTS7, like other 
ADAMTS family members, can cleave itself. 
Whether this occurs in vivo needs further 
investigation. Autolysis of ADAMTS proteins has 
so far only been demonstrated in conditioned media 
and purified ADAMTS proteases. Where 
conditioned media was used to demonstrate 
autolysis, the involvement of proteolytic cascades 
cannot be completely ruled out.  
It has previously been shown that ADAMTS 
activity can be regulated by TIMPs. This has so far 
only been shown for TIMP-3, which inhibits 
ADAMTS4 and 5 efficiently (14,38). TIMP-3 
inhibits ADAMTS2 very poorly  (14) and 
ADAMTS13 and ADAMTS15 are not inhibited by 
any of the TIMPs (39). TIMP-4 does not inhibit 
ADAMTS1, 4 or 5 efficiently (38,40,41). 
Surprisingly, we showed that TIMP-4 is the most 
efficient inhibitor of ADAMTS7, although TIMP-
3 also showed inhibitory activity. Importantly, 
TIMP4 inhibited ADAMTS7 efficiently at low nM 
concentrations, suggesting that this could 
potentially function as the endogenous inhibitor of 
ADAMTS7. Both TIMP-4 and ADAMTS7 have a 
restricted tissue distribution with particularly 
abundant expression in adult cardiac tissue (42,43), 
which is therefore a likely site of physiological 
activity and regulation. Interestingly, Timp4-/- mice 
are more vulnerable to myocardial infarction (44). 
Our findings suggest unregulated ADAMTS7 may 
potentially contribute to this phenotype. 
Our TAILS analysis identified 45 candidate 
substrates of ADAMTS7 and in this study we 
confirmed proteolysis of LTBP4 and autolysis.  
Whether the other ECM proteins identified are 
susceptible to proteolysis by ADAMTS7 needs 
confirmation. One of these, LTBP3, appeared to be 
cleaved in the same N-terminal linker region as 
LTBP4. However, the physiological consequence 
of LTBP3 proteolysis is not immediately clear. The 
primary function of LTBP3 is reportedly to 
influence the bioavailability of TGFβ, in cartilage 
and bone in particular (45). The high MW, latent 
forms of TGFβ1-3, bind to the middle 8-Cys/TB 
domain of LTBP3. Mutations in LTBP3 cause 
dental anomalies and short stature but also appear 
to increase risk of thoracic aortic aneurysms and 
dissections (46,47). Binding sites on LTBP3 for 
fibrillin-1 and/or other ECM molecules have not 
been identified, suggesting that the effect of 
proteolysis may be distinct from the effect on 
LTBP4. 
Interestingly, LTBP1 was also identified as a 
potential ADAMTS7 substrate. LTBP1 exists in 
two major forms: long (-L )and short (-S), which 
are transcribed from independent promoters and 
differ in their N-terminus only (48). The apparent 
cleavage site, as suggested by our TAILS analysis, 
is present in the long form (K318-G319), but not in 
the short form. Although the potential consequence 
of proteolysis at this site needs characterisation, it 
is interesting that the long form of LTBP1 
(LTBP1L) is primarily important for cardiac and 
cardiac valve development (49,50). 
For COMP, previously reported to be 
susceptible to proteolysis by ADAMTS7 (15), our 
TAILS analysis did not identify cleavage products. 
COMP was expressed by the cells, as the peptide 
containing the N-terminus of secreted COMP 
(following removal of the signal peptide) was 
identified. Using recombinant COMP, we 
previously found that the ADAMTS7 
concentration required for proteolysis of COMP is 
>500nM (51), which likely exceeds the 
concentration of ADAMTS7 in our TAILS 
experiment and is much higher than what is 
required to cleave LTBP4 (<10nM). 
In conclusion, we identified and confirmed a 
novel substrate of ADAMTS7, LTBP4, the 
cleavage of which has the potential to impact on 
elastogenesis, and consequently, elasticity in the 
cardiovascular system. We shed light on the 










ADAMTS7 substrate specificity 
6 
 
previously unknown cleavage site specificity of 
ADAMTS7 and identified TIMP-4 as an efficient 
inhibitor, which makes it a likely cardiovascular 
regulator of ADAMTS7. The autolytic reactions 
that we report here, may provide an additional 
mode of regulation. Several other candidate 
substrates that were identified by TAILS, are of 
potential interest and require further investigation. 
 
Experimental procedures 
Generation of expression vectors 
Human ADAMTS7 cDNA was obtained 
from Source Bioscience (I.M.A.G.E. clone 
6650221). The cDNA, including the native signal 
peptide, was cloned into the pcDNA3.1myc/His 
expression vector, which adds a myc and 6xHis tag 
at the C-terminus. Truncated ADAMTS7 variants 
were truncated after the following amino acids: 
Pro997 (T4), Gly1414 (Mu), Pro1630 (T8).  Point 
mutants were generated by site directed 
mutagenesis (KOD Hotstart, Merck). The 
ADAMTS7-T4 furin cleavage site mutant (FCSM) 
contains the mutations 
R68A/R70A/R232A/R236A. The coding sequence 
of all constructs that were generated was verified 
by Sanger sequencing (Genewiz UK Ltd).  The 
mammalian expression vector for LTBP4S-A was 
a generous gift of Tomoyuki Nakamura (Kansai 
Medical University, Osaka, Japan) and details of its 
generation have been described previously (21).   
 
iTRAQ-TAILS 
The conditioned medium (serum free 
Dulbecco’s Modified Medium) of human skin 
fibroblasts co-cultured with HEK cells stably 
expressing ADAMTS7-Mu or inactive 
ADAMTS7-Mu (E389Q) was prepared for 
proteomic analysis by LC-MS/MS as previously 
described (52). Briefly, for each experimental 
condition, 3.5 x 107 HEK cells and 3.3 x 107 
fibroblasts were co-cultured in serum free 
Dulbecco’s Modified Medium supplemented with 
amino acids and vitamin C. 120 ml of conditioned 
medium was harvested per condition and protease 
inhibitors AEBSF (0.1 mM) and EDTA (1mM) 
were added. The conditioned medium was 
concentrated 100x and 500 ug of total protein was 
denatured with 2.5 M GuHCl, prior to reduction 
with 1mM tris(2-carboxyethyl)phosphine) at 65°C 
for 45 mins. Cysteines were alkylated with 5 mM 
iodoacetamide for 1 hour at room temperature in 
the dark. Free amines, including those of neo-N-
termini generated by ADAMTS7, were labelled 
with iTRAQ® labels. Proteins recovered from the 
“active protease condition” and from the “inactive 
control condition” were labelled with 2.5 mg 
iTRAQ® 115 or iTRAQ® 117 respectively. After 
trypsinization with Trypsin Gold (Promega), most 
peptides not labelled with iTRAQ were removed by 
coupling to the amine reactive polymer HPG-ALD 
(Flintbox) and centrifugal filtration (Amicon Ultra 
10kDa MWCO). Mass spectrometry was 
performed with an ESI-Q Exactive mass 
spectrometer (coupled to 2D-RP/RP NanoAcquity 
UPLC) at the Proteomic Facility of the University 
of Liège. For data analysis, the open source Trans-
Proteomic Pipeline (TPP) was used. Peptides of 
potential interest (Appendix, Table S1) were 
selected based on labelling at the N-terminus with 
iTRAQ and overrepresentation in the protease 
condition (>1.5x) vs control condition. Excluded 
were peptides that mapped to native N-termini or 
N-termini immediately following signal peptides or 
furin cleavage sites. Also excluded were peptides 
that mapped to proteins that are not secreted.  
 
Expression and purification of ADAMTS7 and 
LTBP4 
ADAMTS7, ADAMTS7 variants and 
LTBP4S-A were transiently expressed in 
HEK293T cells in OptiMEM (Invitrogen) using 
PEI MAX 40K (Polysciences, Inc) as a transfection 
reagent. HEK cells stably expressing ADAMTS7-
Mu, ADAMTS7-Mu (E389Q), and ADAMTS7-T8 
were generated using G418 (Sigma Aldrich) as a 
selection reagent.  ADAMTS7-T8 was purified 
using anion exchange chromatography and gel 
fitration (53). Briefly, 1L conditioned medium was 
loaded at pH 7.8, followed by washing of the 
column with 705 mM NaCl, 20 mM Tris (pH 7.8), 
10 mM CaCl2 and eluting with 2M NaCl, 20 mM 
Tris, pH 7.8 10 mM CaCl2. Gel filtration 
chromatography was employed using a HiPrep 
Sephacryl S-200 HR column for further 
purification and exchanging the buffer into 20mM 
Tris, 150 mM NaCl, 10 mM CaCl2. Protein purity 
was assessed by SDS-PAGE/Coomassie staining. 
Eluted fractions were concentrated 5x using 
Amicon Ultra centrifugal filter units (MWCO 100 
kDa) and the purified enzyme was aliquoted and 
stored at -80 °C until use in proteolytic activity 
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assays. LTBP4S-A was purified using ANTI-
FLAG® M2 Affinity Gel (Sigma Aldrich) using 
Flag peptide (Sigma Aldrich) for elution. 
  
SDS-PAGE and Western blotting 
For SDS-PAGE analysis, Bolt™ 4-12% 
(ADAMTS7) or 12% (LTBP4S-A) Bis-Tris Plus 
Gels (Thermo Fisher) were used. Samples were 
reduced with 5% β-mercaptoethanol where 
indicated. ADAMTS7 and ADAMTS7 variants 
were detected with anti-myc Ab (9E10, Santa Cruz 
biotechnology). LTBP4S-A was recognised with 
anti-Flag (OctA probe) Ab sc-66355 (Santa Cruz 
biotechnology). All primary antibodies were used 
at 0.2µg/ml in phosphate buffered saline (PBS), 5% 
nonfat dried milk powder and detected with 
appropriate horseradish peroxidase (HRP) labelled 
secondary Ab (DAKO). Immobilon 
Chemiluminescent HRP substrate (Merck 
Millipore) was detected with a Chemidoc Touch 
Imaging system (Bio-Rad). For Coomassie 
staining, gels were stained for 2 hours with Thermo 
Fisher Imperial protein stain and destained in water 
overnight at room temperature on an orbital shaker. 
Treatment of ADAMTS7-T4 CM with 
recombinant human furin (PeproTech) was 
performed at a final furin concentration of 50 nM.  
 
N-terminal sequencing of ADAMTS7 autolytic 
product 
ADAMTS7-T4 was expressed at a large 
scale (0.5 L), purified using a Ni2+-chelating 
column (HiTRAP, GE Healthcare), and eluted 
using an Imidazole gradient (20-250mM). 
Fractions containing ADAMTS7-T4 and its c-
terminal autolytic product were identified using dot 
blot with the anti-Myc Ab (Santa Cruz). Protein 
purity of these samples was assessed by SDS-
PAGE/Silver staining. Samples were dialysed 
against 20mM Tris, pH 7.5, 150 mM NaCl, 5 mM 
CaCl2, and concentrated 10x using Amicon Ultra 
centrifugal filter units, MWCO 10 kDa (Merck). 
ADAMTS7-T4 and its C-terminal autolytic 
product were separated by SDS-PAGE using 
Bolt™ 4-12% Bis-Tris Plus Gels (Thermo Fisher) 
and transferred to PVDF (Millipore Immobilon 
PSQ) with Bolt Transfer Buffer (ThermoFisher) 
and Trans-Blot® Turbo™ Transfer Instrument 
(Bio-Rad). Protein bands were visualised with 
Ponceau S staining (Amresco) and the 45 kDa 
autolytic product band was excised and sent to 
Alphalyse A/S (Denmark) for N-terminal 
Sequencing.  
 
Molecular modelling of ADAMTS7 
The structure of the N-terminal domains 
(MP-Spacer) of ADAMTS7 was modelled with the 
Bioinformatics Toolkit of the Max Planck Institute 
for Developmental Biology, Tübingen, Germany 
(54,55). The templates used for modelling were the 
ADAMTS structures: 3GHM, 2RJQ, 2RJP, 4WK7 
and 2V4B. Molecular graphics were produced with 
an open source version of Pymol precompiled by 
Christoph Gohlke (University of California, 
Irvine).  
 
LTBP4S-A cleavage assays 
Purified LTBP4S-A (10µM) was incubated 
at 37° C with or without the indicated concentration 
of purified ADAMTS7-T8 in 20mM Tris (pH7.5), 
150mM NaCl, 10mM CaCl2 for the specified 
period of time. The indicated concentrations of 
purified ADAMTS7-T8 used in the assays are the 
concentration of active protease as determined by 
active-site titration with TIMP-4. Where TIMPs 
were used in the assay, recombinant human 
TIMP1, 2, 3 or 4 (R&D systems) were pre-
incubated with ADAMTS7-T8 for 1 hour at 37° C. 
Proteolysis was stopped by addition of Bolt™ LDS 
Sample Buffer, 5% β-mercaptoethanol and heating 
to 95° C. Samples were frozen at -20° C until 
analysis by SDS-PAGE/Coomassie. To measure 
TIMP-4 inhibition, proteolysis was quantified by 
densitometry using ImageJ.   
 
Active site titration of ADAMTS7-T8 
TIMP-4 was titrated into the LTBP4SA 
cleavage assays at concentrations ranging 1.75 nM 
– 60 nM and relative activity was plotted against 
TIMP-4 concentration to establish the 
concentration of active protease in purified 
ADAMTS7-T8 stock solutions retrospectively 
(56).   
 
Identification of LTBP4S-A cleavage sites 
Purified LTBP4S-A (80 µg) was incubated 
for 25 h with 70 nM purified ADAMTS7-T8 in 50 
mM HEPES (pH 7.5), 5 mM CaCl2 in the presence 
or absence of broad spectrum metaloprotease 
inhibitor GM6001 (90 uM). Samples were analysed 
by SDS-PAGE/Coomassie to confirm proteolysis 
and the absence thereof in the cleavage and control 
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condition respectively. New N-termini generated 
by ADAMTS7 were labelled with Tandem Mass 
Tags (ThermoFisher) according to the 
manufacturer’s instructions prior to incomplete 
digest with Trypsin (ThermoFisher), Chymotrypsin 
(ThermoFisher) and Glu-C (ThermoFisher). LC-
MS/MS was performed at the Proteomic Facility of 
the University of Liège using an Acquity M-Class 
UPLC (Waters) hyphenated to a Q Exactive 
(Thermo Scientific), in nanoelectrospray positive 
ion mode. Data were analysed with Proteome 
Discoverer version. 2.1.1.21. The protein/peptide 
identifications were performed against a Bovine 
background protein database supplemented with 
the sequence of the human target protein LTBP4. 
Search parameters were set as “no Enzyme” due to 
the specific Multi Enzymatic Limited Digestion 
(MELD) that was applied. Scissile bonds were 
derived from peptides labelled with TMT at the N-
terminus that were identified in the active protease 
condition, but not in the control condition. All 
reported peptides have a False Discovery Rate 
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Figure 1. ADAMTS7 constructs. (A) Domain organisation of ADAMTS7. The ADAMTS7 zymogen 
contains a Prodomain that maintains latency until, upon secretion, furin cleaves at two sites in the Prodomain 
to generate the mature active form. The metalloprotease domain (MP) contains the active site. The ancillary 
domains consist of eight thrombospondin type 1 (TSP-1) domains (numbered), a cysteine-rich domain (Cys), 
Spacer (Sp), mucin-like (Mu) and a protease and lacunin (PLAC) domain. The Mucin-like domain has a 
chondroitin sulphate (CS) chain attached. (B) Recombinant ADAMTS7 and truncated variants were 
generated with a C-terminal Myc and His6 tag. (C) Western blot of recombinant ADAMTS7 and truncated 
variants, detected with an anti-myc tag Ab. The expression of full length ADAMTS7 was very poor and 
conditioned medium was concentrated ~100x for visualisation on Western blot.  
  















Figure 2. Western blot of ADAMTS7-T4 confirms autolysis as revealed by TAILS. (A) Autolysis can be 
prevented either by inactivating ADAMTS7 or by abolishing activation by furin. Western blot (reducing) of 
conditioned medium containing ADAMTS7-T4, detecting with anti myc-tag Ab, shows zymogen (Z), a 
mature (M) form and a 45 kDA autolytic product (A.P). Conditioned medium was loaded after 2H incubation 
with either buffer (Lane 1) or 50 nM recombinant furin (Lane 2). Decanoyl-RVKR-CMK is an inhibitor of 
furin which was added to the medium (10 µM) post transfection to prevent conversion of the latent zymogen 
to its active (mature) form (Lane 3). Activation was also abolished in the furin cleavage site mutant FCSM 
(R68A/R70A/R232A/R236A) (Lane 4). The mutation E389Q in the active site of the metalloprotease domain 
abolishes proteolytic activity and, consequently the appearance of the 45 kDa autolytic product (lane 5). (B) 
The P1 residues of the autolytic cleavage sites identified by TAILS and N-terminal sequencing were mutated 




Figure 3. Structural model of ADAMTS7 MP-Spacer domains. The model of the ADAMTS7 Spacer domain 
structure revealed that the autolytic cleavage sites identified by N-terminal sequencing and TAILS (Glu729-
Val730 and Glu732-Ala733) are present in the surface exposed β3-β4 loop of the Spacer domain. The active-
site zinc in the MP domain is shown in blue, structural calcium ions are shown in green. The structure of the 
N-terminal domains of ADAMTS7 (Mp-Spacer) was modelled using the Dis-Spacer structure of 
ADAMTS13 (3GHM) and ADAMTS1, 4 and 5 MP domain structures (2RJQ, 2RJP, 4WK7, 2V4B).  
















Figure 4.  Identification of LTBP4 as a substrate of ADAMTS7. (A) Domain organisation of LTBP3 and 
LTBP4S, which is the shorter isoform of LTBP4, indicating the location of the scissile bonds (red arrow) that 
were identified by TAILS. LTBP4S-A is a truncated recombinant variant that contains an N-terminal Flag-
tag. For the linker region that contains the identified scissile bonds, an alignment of the amino acid sequence 
of LTBP3 and LTBP4 is shown, indicating the scissile bonds (red arrows). (B) Western blot of LTBP4S-A 
conditioned media (anti FLAG Ab) incubated for 17H with buffer (CTRL), purified ADAMTS7-T8 (40nM), 
ADAMTS7-Mu conditioned medium, or ADAMTS7-Mu (E389Q) conditioned medium. (C). Coomassie 
stained SDS-PAGE gel of purified LTBP4S-A (10 µm) incubated with 10 nM purified ADAMTS7-T8 for 0, 
8, 17 and 25 hours. (D) Amino acid sequence of LTBP4S-A highlighting scissile bonds cleaved by 
ADAMTS7 (indicated by / and highlighted in yellow) as identified by LC-MS/MS analysis following TMT 
labelling of cleaved and uncleaved LTBP4S-A.  
  














Figure. 5.  Inhibition of ADAMTS7 by Tissue Inhibitors of Metalloproteinases (TIMP). (A)  ADAMTS7-T8 
(9nM) was incubated with LTBP4S-A (20µM) at 37°C for 17 hours in the absence or presence of 60 or 
300nM TIMP1,2,3 or 4 and proteolysis was monitored by SDS-PAGE/Coomassie. (B)  Various 
concentrations (1.75-60nM) of TIMP-2 (green triangles), TIMP-3 (pink diamonds) or TIMP-4 (blue circles) 
were incubated with 18 nM ADAMTS7 and 10µM LTBP4S-A for 17 hours and inhibition of proteolysis was 
monitored by densitometry of LTBP4S-A on SDS-PAGE/Coomassie. The derived Ki(app) for TIMP-4 was 13 
nM, compared to 49 nM for TIMP-3 and >100 nM for TIMP-2. Data represent average ±SEM (n=3).  
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Table S1. Candidate substrates of ADAMTS7 identified by TAILS 
Secreted and transmembrane proteins containing neo-N-termini that were enriched in the presence of active recombinant ADAMTS7 vs 
inactive ADAMTS7(E389Q). Listed is 1) the ID of the protein in the UniProt database, 2) the full name of the protein, 3) whether the protein 
is a secreted (S) or a transmembrane (TM) protein, 4) the P1 residue preceding the identified peptide, 5) the amino acid sequence of the 
identified peptide, 6) the intensity ratio of iTRAQ labels originating from the protease (P) and control (C) condition and 7) the location of the 
new N-terminus in the structure of the identified protein. ADAMTS7 peptides are listed separately in Table S2.  
UniProt 
ID 
Protein name TM/S P1 Peptide P:C Location new N-terminus 
O95450 
A disintegrin and 
metalloproteinase with 
thrombospondin motifs 2 
S A42 ADPPGGPLGHGAER 1.9 Prodomain 
O00468 Agrin S K1863 SAGDVDTLAFDGR 1.6 
Loop connecting EGF-like 4 and Laminin G-
like 3 domains 
P22004 Bone morphogenetic protein 6 S A35 AAAAGGQLLGDGGSPGR 2.4 Propeptide 
Q9NYQ6 
Cadherin EGF LAG seven-pass 
G-type receptor 1 
TM R62 ELLDVGR 1.6 Unknown structure 
O75976 Carboxypeptidase D S G227 EPPALDEVPEVR 3.4 Loop in Peptidase M14 domain 
P16870 Carboxypeptidase E S R42 LQQEDGISFEYHR 1.7 
N-terminus preceding Peptidase M14  
domain 
P07858 Cathepsin B S K79 LPASFDAR 1.7 
Loop connecting propeptide with cysteine 
peptidase domain 
P10909 Clusterin S R325 ELDESLQVAER 1.8 Clusterin domain 
P10909 Clusterin S A266 FQHPPTEFIR 1.8 Clusterin domain 
P10909 Clusterin S P265 AFQHPPTEFIR 1.5 Clusterin domain 
P02452 Collagen alpha-1(I) chain S A1218 DDANVVR 1.6 
Loop preceding C-terminal prodomain. 
(BMP1 cleavage site) 
P02452 Collagen alpha-1(I) chain S G174 ISVPGPMGPSGPR 1.5 
Non-helical region following the n-terminal 
propeptide 
P02452 Collagen alpha-1(I) chain S K781 GESGPSGPAGPTGAR 1.6 Triple-helical region 
P02452 Collagen alpha-1(I) chain S R1217 ADDANVVR 1.5 Loop preceding C-terminal prodomain 
P02461 Collagen alpha-1(III) chain S N1251 GQIESLISPDGSR 1.6 C-terminal propeptide (Stalk region) 
P20908 Collagen alpha-1(V) chain S P435 ANQDTIYEGIGGPR 1.9 Nonhelical region 
P39060 Collagen alpha-1(XVIII) chain S A1533 DDILASPPR 2.1 NC1 hinge region. Releases endostatin. 
P08123 Collagen alpha-2(I) chain S P983 SGPVGPAGAVGPR 1.6 Triple helical region 
P08572 Collagen alpha-2(IV) chain S G1353 FMGNTGPTGAVGDR 1.9 Triple-helical region 
P05997 Collagen alpha-2(V) chain S G213 SVGPVGPR 2.7 Triple-helical region 
P12111 Collagen alpha-3(VI) chain S G2240 LIGEQGISGPR 2.2 Collagen-like region 
P01034 Cystatin-C S R34 LVGGPMDASVEEEGVR 3.2 
N-terminal region. Proteolysis may affect 
inhibitory function.  
Q9NT22 EMILIN-3 S V224 GFGVIPEGLVGPGDR 2.0 Unknown structure 
P54756 Ephrin type-A receptor 5 TM A55 SPSNEVNLLDSR 1.7 Prior to Eph LBD domain 
Q8IWU6 Extracellular sulfatase Sulf-1 S N558 LEEEEELQVLQPR 4.8 PFAM predicted domain DUF3740 
Q8IWU6 Extracellular sulfatase Sulf-1 S Y555 DINLEEEEELQVLQPR 2.4 PFAM predicted domain DUF3740 
Q8IWU5 Extracellular sulfatase Sulf-2 S Y549 HVGLGDAAQPR 2.2 PFAM predicted domain DUF3740 
P35556 Fibrillin-2 S N781 GICENLR 1.6 EGF-like 11 domain 
P35556 Fibrillin-2 S R48 SATAGSEGGFLAPEYR 2.5 Propeptide 
P02751 Fibronectin S T279 SSGSGPFTDVR 1.7 
Loop connecting Fibronectin type-I 5 and 
Fibronectin type-I 6 domains 
P02751 Fibronectin S S281 GSGPFTDVR 4.8 
Loop connecting Fibronectin type-I 5 and 
Fibronectin type-I 6 domains 
Q86VR8 Four-jointed box protein 1 S L84 TLAAGADGPPR 1.5 Unknown structure 
P22466 Galanin peptides S L109 DLPAAASSEDIER 2.7 
Galanin message associated peptide 
(GMAP) 
Q08380 Galectin-3-binding protein S K441 YSSDYFQAPSDYR 2.2 Unknown structure 
S3 
 
Q08380 Galectin-3-binding protein S R128 STHTLDLSR 1.8 Loop connecting SRCR and BTB domains 
Q08380 Galectin-3-binding protein S Y446 FQAPSDYR 2.7 Unknown structure 
P28799 Granulins S A201 LSSSVMCPDAR 1.5 Loop connecting granulin F and Granulin B 
P28799 Granulins S S203 SSVMCPDAR 1.5 Loop connecting granulin F and Granulin B 
P28799 Granulins S S204 SVMCPDAR 1.7 Loop connecting granulin F and Granulin B 
P28799 Granulins S S205 VMCPDAR 1.7 Loop connecting granulin F and Granulin B 
P30443 
HLA class I histocompatibility 
antigen, A-1 alpha chain 
TM V49 GYVDDTQFVR 1.8 Alpha-1 region 
P08476 Inhibin beta A chain S N98 GYVEIEDDIGR 1.7 Propeptide 
P05019 Insulin-like growth factor I S A48 GPETLCGAELVDALQFVCGDR >>1 
Loop connecting N-terminal propeptide with 
IGF I 
Q08431 Lactadherin S N34 GGLCEEISQEVR 1.6 EGF-like domain 
P25391 Laminin subunit alpha-1 S C873 LGNTDGAHCER 8.1 Laminin EGF-like 8 
Q14766 
Latent-transforming growth 
factor beta-binding protein 1 
S K318 GISGEQSTEGSFPLR 2.6 




factor beta-binding protein 3 
S E220 VQAPPPVVNVR 1.9 




factor beta-binding protein 4 
S E229 ASVVVHQVER 2.1 
Loop connecting EGF-like domain and 
hybrid domain 
Q68D85 
Natural cytotoxicity triggering 
receptor 3 ligand 1 
TM P110 GIQLEEAGEYR 1.8 Ig-like V-type domain 
O95502 Neuronal pentraxin receptor TM C21 IIASVPLAASPAR 2.2 
Loop connecting Signal-anchor with 
Extracellular region 
P14543 Nidogen-1 S N233 GAYNIFANDR 1.6 NIDO (G1) domain 
P07602 Prosaposin S N194 GDVCQDCIQMVTDIQTAVR 1.9 
Loop connecting propeptide with Saposin B-
type 2 domain 
O15354 Prosaposin receptor GPR37 TM R73 EEQGAAFLAGPSWDLPAAPGR 1.8 Extracellular region 1  
O75629 Protein CREG1 S R45 LPPLPPR 1.9 Loop preceding β-barrel 
Q92520 Protein FAM3C S R41 SALDTAAR 1.6 Known maturation site removing N-terminus 
Q04900 Sialomucin core protein 24 TM T54 TPAPETCEGR 1.7 Extracellular region 
O00391 Sulfhydryl oxidase 1 S R645 DTGAALLAESR 1.5 Unknown structure 
Q6ZMP0 
Thrombospondin type-1 
domain-containing protein 4 
(ADAMTSL6) 
S R98 AFADHVVSAVR 2.1 









Table S2. ADAMTS7 peptides identified by TAILS suggesting autolysis 
Neo-N-termini in ADAMTS7 itself that were enriched in the presence of active ADAMTS7 vs inactive ADAMTS7(E389Q) 
suggest autolysis. Listed are 1) the domain in which the new N-terminus is located 2) the P1 residue preceding the identified 
peptide sequence 3) the sequence of the identified peptide 4) the intensity ratio of iTRAQ labels originating from the active 











Domain P1 Peptide P:C  
spacer E706 AEGLGYVDVGLIPAGAR 3.3 
spacer E708 GLGYVDVGLIPAGAR 4.3 
spacer G709 LGYVDVGLIPAGAR 10.3 
spacer G711 YVDVGLIPAGAR 4.8 
spacer Y712 VDVGLIPAGAR 30.0 
spacer V713 DVGLIPAGAR 3.4 
spacer E729 VAEAANFLALR 92.2 
spacer V730 AEAANFLALR 2.7 
spacer A731 EAANFLALR 3.5 
spacer E732 AANFLALR 39.8 
spacer N758 GDYQVAGTTFTYAR 5.7 
spacer E797 SNPGVHYEYTIHR 2.2 
TSP type-1 4 C977 DEAQQPASEVTCSLPLCR >>1 
TSP type-1 4 P983 ASEVTCSLPLCR 18.2 
mucin-like N1194 DFPVGKDSQSQLPPPWR 4.3 
mucin-like K1357 GQPESLSPEVPLSSR 3.7 
mucin-like L1398 AEAGPPADPLVVR 2.2 
mucin-like A1399 EAGPPADPLVVR 4.2 
Domain P1 Peptide P:C  
prodomain R40 AALDIVHPVR 4.8 
prodomain R76 DAPAFYELQ >>1 
prodomain R76 DAPAFYEL 4.8 
prodomain R76 DAPAFYELQYR 3.4 
prodomain P79 AFYELQYR 2.6 
prodomain T96 ANQHLLAPGFVSETR 3.2 
prodomain N98 QHLLAPGFVSETR 4.4 
prodomain Q99 HLLAPGFVSETR 7.8 
prodomain L101 LAPGFVSETR 4.0 
prodomain Q194 RGDSSAPSTCGVQVYPELESR 2.5 
prodomain R195 GDSSAPSTCGVQVYPELESR 6.2 
prodomain P201 STCGVQVYPELESR 22.6 
prodomain C204 GVQVYPELESR 4.8 
prodomain C204 GVQVYPELESRR 3.0 
prodomain G205 VQVYPELESR 3.7 
prodomain Q207 VYPELESR 5.8 
MP G328 GDAHPLHHDTAILLTR 2.2 
MP R370 SCSINEDTGLPLAF 3.6 
Dis H504 SKLDAAVDGTR 5.4 
Dis K506 LDAAVDGTR 29.4 
cysteine-rich N637 EYFAEKLR 4.3 
cysteine-rich D646 AVVDGTPCYQVR 3.1 
cysteine rich A647 VVDGTPCYQVR 55.2 
cysteine-rich D650 GTPCYQVR 3.6 
cysteine-rich G673 CDFEIDSGAMEDR 6.0 
cysteine-rich G673 CDFEIDSGAMEDR 3.0 
S5 
 
Table S3.  LTBP4 scissile bonds cleaved by ADAMTS7. Following LTBP4S-A incubation with ADAMTS7-T8 in 
the presence (control) or absence of a zinc-chelating small molecule inhibitor, samples were labelled with amine-
reactive mass tags (TMT), which labels new N-termini generated by ADAMTS7. After subsequent incomplete 
digest with Trypsin, Chymotrypsin, and Glu-C, samples were analyzed by LC-MS/MS. Listed are the peptides 
labelled with TMT at the N-terminus that were found to be abundant in the active protease condition (no inhibitor) 
but completely absent in the control condition (with inhibitor). The P1 residue preceding the identified peptide is 
listed with the numbering of LTBP4S (UniProt ID: Q8N2S1-2). Note that using this numbering the P1 residue 
identified in the original TAILS experiment (Table S1) is E162.  
 
P1 Peptide 
G73 AAPGGPGF 
G119 ARPPAPAVPGLTR 
P138 LANHRDDEHGVAS 
P138 LANHRDDEHGVASMVSVHVEHPQEASVVVHQVER 
S164 VVVHQVER 
A184 VARAEAAARAE 
R187 AEAAAR 
R187 AEAAARAEAAAP 
R193 AEAAAPYT 
R193 AEAAAPYTV 
E195 AAAPYTVLAQ 
E195 AAAPYTVLAQSAPREDG 
E195 AAAPYTVLAQSAPREDGYSD 
A196 AAPYTV 
A196 AAPYTVLAQSAPR 
A196 AAPYTVLAQSAPREDG 
A197 APYTVLAQSAPR 
P199 YTVLAQSAPR 
T201 VLAQSAPR 
